

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	PYC THERAPEUTICS LIMITED
ABN	48 098 391 961

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Dr Rohan Hockings
Date of last notice	13 January 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder)	N/A
Date of change	06 March 2026
No. of securities held prior to change	133,350 Ordinary Shares
Class	Ordinary Shares
Number acquired	80,010 Ordinary Shares
Number disposed	NIL
Value/Consideration	\$120,015
No. of securities held after change	213,360 Ordinary Shares
Nature of change	Participation in Retail Entitlement Offer.

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	13 January 2026 – Offer Invitation under the terms of the Company's Long Term Incentive Plan
Nature of interest	Subject to shareholder approval. To be issued 1,500,000 unlisted options exercisable by payment of \$2.52 each on or before the date that is 48 months from the date of issue. Fifty percent of the options will vest 12 months from the date of issue and fifty percent will vest 24 months from the date of issue.
Name of registered holder (if issued securities)	N/A

⁺ See [chapter 19](#) for defined terms.

Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See [chapter 19](#) for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	PYC THERAPEUTICS LIMITED
ABN	48 098 391 961

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Professor Ian Constable
Date of last notice	9 January 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder)	Hyphema Pty Ltd as trustee for the Constable Family Trust (director and beneficiary)
Date of change	06 March 2026
No. of securities held prior to change	205,000 Ordinary Shares
Class	Ordinary Shares
Number acquired	123,000 Ordinary Shares
Number disposed	NIL
Value/Consideration	\$184,500
No. of securities held after change	328,000 Ordinary Shares
Nature of change	Participation in Retail Entitlement Offer.

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	8 January 2026 – Offer Invitation under the terms of the Company's Long Term Incentive Plan.
Nature of interest	Subject to shareholder approval, to be issued 1,000,000 unlisted options exercisable by payment of \$1.80 each on or before the date that is 48 months from the date of issue. Fifty percent of the options will vest 12 months from the date of issue and fifty percent will vest 24 months from the date of issue.
Name of registered holder (if issued securities)	N/A

⁺ See [chapter 19](#) for defined terms.

Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A